PolyPid (PYPD) Consolidated Net Income (2019 - 2026)
PolyPid's (PYPD) quarterly Consolidated Net Income came in at $7.8 million in Q2 2026, down 20.55% year-over-year from $9.9 million in Q2 2025, and up 1.49% quarter-over-quarter from $7.7 million in Q1 2026.
Analysis
PolyPid (PYPD) Consolidated Net Income (2019 - 2026) Analysis & Trends
PolyPid has disclosed Consolidated Net Income across 8 years of filings, most recently posting $7.8 million for Q2 2026.
- In Q2 2026, Consolidated Net Income fell 20.55% year-over-year to $7.8 million; the TTM figure through Jun 2026 stood at $31.6 million (down 7.92% YoY), while the FY2025 annual figure was $34.2 million, up 18.04% from the prior year.
- Consolidated Net Income came in at $7.8 million for Q2 2026 at PolyPid, up from $7.7 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $11.9 million in Q1 2022 to a low of $5.6 million in Q3 2023.
- Average Consolidated Net Income over 5 years is $7.9 million, with a median of $7.7 million recorded in 2024.
- Year-over-year, Consolidated Net Income plunged 52.18% in 2022 and soared 56.93% in 2025.
- Over 5 years, Consolidated Net Income stood at $6.5 million in 2022, then fell by 1.84% to $6.3 million in 2023, then soared by 34.02% to $8.5 million in 2024, then gained by 1.66% to $8.6 million in 2025, then declined by 9.17% to $7.8 million in 2026.
- Per Business Quant data, the three most recent Consolidated Net Income figures were $7.8 million in Q2 2026, $7.7 million in Q1 2026, and $8.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -290.61 Mn |
| 10 | PolyPid | 85.52 Mn | 78.75 Mn | - | 7.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.84 Mn |
| Mar 31, 2026 | 7.73 Mn |
| Dec 31, 2025 | 8.64 Mn |
| Sep 30, 2025 | 7.41 Mn |
| Jun 30, 2025 | 9.87 Mn |
| Mar 31, 2025 | 8.25 Mn |
| Dec 31, 2024 | 8.49 Mn |
| Sep 30, 2024 | 7.72 Mn |
| Jun 30, 2024 | 6.29 Mn |
| Mar 31, 2024 | 6.43 Mn |
| Dec 31, 2023 | 6.34 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 5.82 Mn |
| Mar 31, 2023 | 6.02 Mn |
| Dec 31, 2022 | 6.46 Mn |
| Sep 30, 2022 | 9.12 Mn |
| Jun 30, 2022 | 11.85 Mn |
| Mar 31, 2022 | 11.87 Mn |
| Dec 31, 2021 | 13.50 Mn |
| Sep 30, 2021 | 9.94 Mn |